A COMPARISON OF CLOZAPINE AND HALOPERIDOL IN HOSPITALIZED-PATIENTS WITH REFRACTORY SCHIZOPHRENIA
Citation
R. Rosenheck et al., A COMPARISON OF CLOZAPINE AND HALOPERIDOL IN HOSPITALIZED-PATIENTS WITH REFRACTORY SCHIZOPHRENIA, The New England journal of medicine, 337(12), 1997, pp. 809-815
Categorie Soggetti
Medicine, General & Internal
SICI code
0028-4793(1997)337:12<809:ACOCAH>2.0.ZU;2-4
Abstract
Background Clozapine, a relatively expensive antipsychotic drug, is wi
dely used to treat patients with refractory schizophrenia. It has a lo
w incidence of extrapyramidal side effects but may cause agranulocytos
is. There have been no long-term assessments of its effect on symptoms
, social functioning, and the use and cost of health care. Methods We
conducted a randomized, one-year, double-blind comparative study of cl
ozapine (in 205 patients) and haloperidol (in 218 patients) at 15 Vete
rans Affairs medical centers. All participants had refractory schizoph
renia and had been hospitalized for the disease for 30 to 364 days in
the previous year. All patients received case-management and social-re
habilitation services, as clinically indicated. Results In the clozapi
ne group, 117 patients (57 percent) continued their assigned treatment
for the entire year, as compared with 61 (28 percent) of the patients
in the haloperidol group (P < 0.001). As judged according to the Posi
tive and Negative Syndrome Scale of Schizophrenia, patients in the clo
zapine group had 5.4 percent lower symptom levels than those in the ha
loperidol group at all follow-up evaluations (mean score, 79.1 vs. 83.
6; P = 0.02). The differences on a quality-of-life scale were not sign
ificant in the intention-to-treat analysis, but they were significant
among patients who did not cross over to the other treatment (P = 0.00
3). Over a one-year period, patients assigned to clozapine had fewer m
ean days of hospitalization for psychiatric reasons than patients assi
gned to haloperidol (143.8 vs. 168.1 days, P = 0.03) and used more out
patient services (133.6 vs. 97.9 units of service, P = 0.03). The tota
l per capita costs to society were high - $58,151 in the clozapine gro
up and $60,885 in the haloperidol group (P = 0.41). The per capita cos
ts of antipsychotic drugs were $3,199 in the clozapine group and $367
in the haloperidol group (P < 0.001). Patients assigned to clozapine h
ad less tardive dyskinesia and fewer extrapyramidal side effects. Agra
nulocytosis developed in three patients in the clozapine group; all re
covered fully. Conclusions For patients with refractory schizophrenia
and high levels of hospital use, clozapine was somewhat more effective
than haloperidol and had fewer side effects and similar overall costs
. (C) 1997, Massachusetts Medical Society.